

# CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.  
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440  
Email ID: [complianceofficer@concordbiotech.com](mailto:complianceofficer@concordbiotech.com)

December 8, 2025

To The Manager, Listing Department <b>National Stock Exchange of India Ltd.</b> Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department <b>BSE Limited</b> Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
---	---

**Subject: Intimation under Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Early Retirement of Chief Financial Officer (KMP)**

Dear Sir(s),

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform that Mr. Lalit Sethi, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company, vide his letter dated December 8, 2025, has submitted his intention to retire early due to personal reasons, effective close of business hours on January 5, 2026.

Disclosure as per Regulation 30(6) and Schedule III Para A(7C):

1. Name & Position: Mr. Lalit Sethi, Chief Financial Officer (KMP)
2. Reason for Change: Early Retirement due to personal reasons
3. Date of Appointment/Cessation: Cessation w.e.f. close of business hours on January 5, 2026
4. Brief Profile: Not applicable
5. Disclosure of Relationships: Not applicable

An early retirement letter duly signed by him is enclosed along with this intimation.

Please note that, the trading window for dealing in securities of the Company has been closed from Monday, December 08, 2025 till 48 hours.

This is for your information and records.

**For Concord Biotech Limited**

**Ms. Hina Patel**  
**Company Secretary & Compliance Officer**  
**(M. No. A56541)**

Date: December 8, 2025

Mr. Ankur Vaid,  
Joint Managing Director & CEO  
Concord Biotech Limited  
Ahmedabad

**Subject: Notice of Early Retirement from the Position of Chief Financial Officer**

Respected Sir,

It is with gratitude and respect that I wish to inform about my early retirement from the position of Chief Financial Officer at Concord Biotech Limited, effective closing of working hours on January 5, 2026

This decision follows consideration of personal priorities, including family commitments and health, as I approach age 59. During my tenure, I have had the privilege of contributing to Concord's growth in operations, regulatory compliance, and IPO preparations. I remain fully confident in the Company's robust leadership and strategic direction.

I am committed to ensuring a seamless transition, including complete handover of financial statements, compliance documentation, regulatory files, and investor relations materials. Please consider this my formal notice in accordance with company policy.

Thank you for the opportunity to serve Concord Biotech Limited. I wish the Board, management team, and all employees continued success.

Yours sincerely,



Lalit Sethi

Chief Financial Officer